Meghan Lee

Meghan Lee

Auto-generated profile, based on publicly available information

Meghan Lee

Department of Internal Medicine, Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
SGShruti Gupta
Shruti Gupta
SSSamuel A P Short
Samuel A P Short
MSMeghan E Sise
Meghan E Sise
JPJason M Prosek
Jason M Prosek
SMSethu M Madhavan
Sethu M Madhavan
DLDavid E Leaf
David E Leaf
Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. Results ICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Conclusions Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.

13 April 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MLMeghan D Lee
Meghan D Lee
HSHarish Seethapathy
Harish Seethapathy
ISIan A Strohbehn
Ian A Strohbehn
SZSophia H Zhao
Sophia H Zhao
GBGenevieve M Boland
Genevieve M Boland
MSMeghan E Sise
Meghan E Sise
Background Current guidelines for treatment of immune checkpoint inhibitor (ICI)-induced nephritis are not evidence based and may lead to excess corticosteroid exposure. We aimed to compare a rapid corticosteroid taper to standard of care. Methods Retrospective cohort study in patients with ICI-induced nephritis comparing a rapid taper beginning with 60 mg/day prednisone and tapered to 10 mg within 3 weeks to a historical control group that began 60 mg/day tapered to 10 mg within 6 weeks (standard of care). Renal recovery was defined as creatinine returning to within 1.5-fold baseline. The log-rank test compared the differences in time to renal recovery between the groups. We report rates of renal recovery at 30, 60 and 90 days, and timing and outcomes of ICI rechallenge. Results Thirteen patients received rapid corticosteroid taper and 14 patients received standard of care. Baseline characteristics were similar between groups. The median time to ≤10 mg/day prednisone was 20 days (IQR 15–25) in the rapid-taper group compared with 38 days (IQR 30–58) in the standard-of-care group. There was no significant difference in the time to renal recovery between the groups, though numerically higher numbers of patients recovered by 30 days, 11 (85%) in the rapid-taper arm versus 6 (46%) in the standard of care arm. Exposure to other nephritis-causing medications (proton pump inhibitor or trimethoprim-sulfamethoxazole) during the corticosteroid taper was more common in the standard of care group, 9 (64%) versus rapid-taper group, 2 (15%), and was associated with longer time to renal recovery, 20 days (IQR 14–101) versus 13 days (IQR 7–34) in those that discontinued nephritis-causing medications. Fifteen (56%) of patients were rechallenged with ICIs, and only two (13%) developed recurrent nephritis. Conclusions Patients with ICI-induced nephritis have excellent kidney outcomes when treated with corticosteroids that are tapered over 3 weeks.

1 September 2021 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
MLMeghan Lee
Meghan Lee
QWQiyu Wang
Qiyu Wang
RWRimda Wanchoo
Rimda Wanchoo
MEMeghana Eswarappa
Meghana Eswarappa
PDPriya Deshpande
Priya Deshpande
MSMeghan E. Sise
Meghan E. Sise

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
HSHarish Seethapathy
Harish Seethapathy
SSSarah Street
Sarah Street
ISIan Strohbehn
Ian Strohbehn
MLMeghan Lee
Meghan Lee
SZSophia H. Zhao
Sophia H. Zhao
MSMeghan E. Sise
Meghan E. Sise